Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis

• Xuan Wang,
• Sheng Yao,
• Jie Dai,
• Li Zhou,
• Hui Feng,
• Jun Guo,
• Xue Bai,
• Lu Si,
• Bixia Tang,
• Chuanliang Cui,
• Xinan Sheng,
• Siming Li,
• Zhihong Chi,
• Lili Mao,
• Bin Lian,
• Xieqiao Yan,
• Yan Kong,
• Xiaowen Wu,
• Xiongwen Tang,
• Keith T Flaherty

Affiliations

Xuan Wang

Baylor Institute for Immunology Research, Dallas, Texas, USA

Sheng Yao

Department of Neurology, Sixth Medical Center of PLA General Hospital, Beijing, China

Jie Dai

Aff28 grid.418961.30000000404722713Regeneron Tarrytown NY USA

Li Zhou

Department of Acupuncture and Moxibustion, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, Hubei, China

Hui Feng

Aff1 grid.64924.3d0000000417605735Cancer Center, The First HospitalJilin University 130061 ChangchunJilin China

Jun Guo

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China

Xue Bai

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China

Lu Si

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China

Bixia Tang

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China

Chuanliang Cui

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China

Xinan Sheng

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China

Siming Li

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China

Zhihong Chi

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China

Lili Mao

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China

Bin Lian

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China

Xieqiao Yan

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China

Yan Kong

School of General Practice, Guangxi Medical University, Nanning, Guangxi, China

Xiaowen Wu

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China

Xiongwen Tang

Medical Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, China

Keith T Flaherty

Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA